1. Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from the Pharmaceutical Sector Scan – the Philippines WHO Harvard Collaborating Center in Pharmaceutical Policy on behalf of The Medicines Transparency Alliance

2. Introduction The Pharmaceutical Sector Scan intends to: Collect, organize, and synthesize data on the Pharmaceutical Sector Highlight availability and gaps in key information Help MeTA stakeholder groups improve transparency in the pharmaceutical sector and to set priorities for future activities November 2011

3. Domains 1) Country Profile 2) Medicines Policy and Regulatory Framework 3) Medicines Market 4) Medicines Financing 5) Medicines Trade 6) Medicines Supply System 7) Medicines Access 8) Medicines Use November 2011

4. Methodology November 2011 Background Scan (International Sources) Background Scan (National Sources) Key Informants for National Data Data Collection Collate and synthesize data Verify Collated Data with Key Informants Formulation of Recommendation

5. November 2011 Domain NameTotal Fields Completed Fields Estimated Fields Data available upon request No data Country Profile: Demographic and Socioeconomic Indicators. Morbidity and mortality 5453100 Medicines Policy and Regulatory Framework 11 000 Medicines Market86200 Medicines Financing2320300 Medicines Trade7561176 Medicines Supply System54330219 Medicines Access116005 Medicines Use3431003

6. Some indicators collated GNI per capita: PhP 80,268.86 – (low to middle income country) Health expenditure as % GDP: 3.8% Population covered PhilHealth (% of total population): 76% according to PhilHealth Practicing Physicians: 3/10,000 population FDA (by virtue of RA 3720 and RA 9711) have 249 regulatory staff nationwide Estimated time to decision (from FDA): – Patented products take around 180 to 270 days (6 to 9 months) – Generic products take around 90 to 180 days (3 to 6 months) November 2011

7. Some indicators collated 40% estimated market share of generic medicines Drug procurement monitoring – Central procurement is monitored – Decentralized procurement has no system Signatory of the World International Property Organizations’ conventions on intellectual property; local IP Laws: RA 8293 and RA 9502 60% of key medicines are available at public health care facilities, 96.7% in private facilities November 2011

8. Key indicators collated On prescribing – RA 6675 (Generics Act of 1988), and DOH AO 1989-062 and 1990-090 – RA 6675 on mandatory inclusion of generic names – PMA Code of Conduct has no specific reference to conduct regarding prescribing medicines 84% of medicines are prescribed by the INN name despite the Generics Act of 1988 mandating all prescriptions to use the generic or INN name. 92.9% of medicines are adequately labeled Only 52.9% of patients know how to take the medicine November 2011

9. Some challenges encountered Conflicting data from various sources Some information not available online Sites are under construction Content unavailable Long gaps between published data and online data Much of the time for data collection was spent on key- informant interviews Of all data fields to be filled 2.59% were based on estimates from experts in the field 3.33% were not disclosed due to privacy reasons and had to be requested 11.48% had no actual data November 2011

10. Conclusions November 2011 The scan is a comprehensive, user friendly tool An extensive source of data on medicine access, use and regulation can be obtained from the scan Performance of the pharmaceutical sector based on internationally accepted indicators of good governance and transparency were described Some obstacles to a total transparency identified

11. Good morning!